189 related articles for article (PubMed ID: 17950450)
1. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Raki M; Särkioja M; Desmond RA; Chen DT; Bützow R; Hemminki A; Kanerva A
Gynecol Oncol; 2008 Jan; 108(1):166-72. PubMed ID: 17950450
[TBL] [Abstract][Full Text] [Related]
2. Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer.
Raki M; Kanerva A; Ristimaki A; Desmond RA; Chen DT; Ranki T; Sarkioja M; Kangasniemi L; Hemminki A
Gene Ther; 2005 Aug; 12(15):1198-205. PubMed ID: 15800658
[TBL] [Abstract][Full Text] [Related]
3. Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer.
Rein DT; Volkmer A; Bauerschmitz G; Beyer IM; Janni W; Fleisch MC; Welter AK; Bauerschlag D; Schöndorf T; Breidenbach M
J Cancer Res Clin Oncol; 2012 Apr; 138(4):603-10. PubMed ID: 22209976
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
[TBL] [Abstract][Full Text] [Related]
5. A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.
Kim KH; Dmitriev IP; Saddekni S; Kashentseva EA; Harris RD; Aurigemma R; Bae S; Singh KP; Siegal GP; Curiel DT; Alvarez RD
Gynecol Oncol; 2013 Sep; 130(3):518-24. PubMed ID: 23756180
[TBL] [Abstract][Full Text] [Related]
6. A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients.
Kim KH; Ryan MJ; Estep JE; Miniard BM; Rudge TL; Peggins JO; Broadt TL; Wang M; Preuss MA; Siegal GP; Hemminki A; Harris RD; Aurigemma R; Curiel DT; Alvarez RD
Hum Gene Ther; 2011 Jul; 22(7):821-8. PubMed ID: 21171861
[TBL] [Abstract][Full Text] [Related]
7. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
[TBL] [Abstract][Full Text] [Related]
8. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus.
Kanerva A; Zinn KR; Chaudhuri TR; Lam JT; Suzuki K; Uil TG; Hakkarainen T; Bauerschmitz GJ; Wang M; Liu B; Cao Z; Alvarez RD; Curiel DT; Hemminki A
Mol Ther; 2003 Sep; 8(3):449-58. PubMed ID: 12946318
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.
Guse K; Ranki T; Ala-Opas M; Bono P; Särkioja M; Rajecki M; Kanerva A; Hakkarainen T; Hemminki A
Mol Cancer Ther; 2007 Oct; 6(10):2728-36. PubMed ID: 17938266
[TBL] [Abstract][Full Text] [Related]
10. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
[TBL] [Abstract][Full Text] [Related]
11. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Bhattacharyya M; Francis J; Eddouadi A; Lemoine NR; Halldén G
Cancer Gene Ther; 2011 Oct; 18(10):734-43. PubMed ID: 21836633
[TBL] [Abstract][Full Text] [Related]
12. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
[TBL] [Abstract][Full Text] [Related]
13. Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter.
Hakkarainen T; Rajecki M; Sarparanta M; Tenhunen M; Airaksinen AJ; Desmond RA; Kairemo K; Hemminki A
Clin Cancer Res; 2009 Sep; 15(17):5396-403. PubMed ID: 19706820
[TBL] [Abstract][Full Text] [Related]
14. Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer.
Onimaru M; Ohuchida K; Nagai E; Mizumoto K; Egami T; Cui L; Sato N; Uchino J; Takayama K; Hashizume M; Tanaka M
Cancer Lett; 2010 Aug; 294(2):178-86. PubMed ID: 20163915
[TBL] [Abstract][Full Text] [Related]
15. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer.
Page JG; Tian B; Schweikart K; Tomaszewski J; Harris R; Broadt T; Polley-Nelson J; Noker PE; Wang M; Makhija S; Aurigemma R; Curiel DT; Alvarez RD
Am J Obstet Gynecol; 2007 Apr; 196(4):389.e1-9; discussion 389.e9-10. PubMed ID: 17403430
[TBL] [Abstract][Full Text] [Related]
16. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
[TBL] [Abstract][Full Text] [Related]
17. Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity.
Kanerva A; Raki M; Ranki T; Särkioja M; Koponen J; Desmond RA; Helin A; Stenman UH; Isoniemi H; Höckerstedt K; Ristimäki A; Hemminki A
J Gene Med; 2007 Jan; 9(1):3-9. PubMed ID: 17149790
[TBL] [Abstract][Full Text] [Related]
18. A Novel CDC25B Promoter-Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models.
Weber HL; Gidekel M; Werbajh S; Salvatierra E; Rotondaro C; Sganga L; Haab GA; Curiel DT; Cafferata EG; Podhajcer OL
Clin Cancer Res; 2015 Apr; 21(7):1665-74. PubMed ID: 25573380
[TBL] [Abstract][Full Text] [Related]
19. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
[TBL] [Abstract][Full Text] [Related]
20. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).
Rocconi RP; Zhu ZB; Stoff-Khalili M; Rivera AA; Lu B; Wang M; Alvarez RD; Curiel DT; Makhija SK
Gynecol Oncol; 2007 Apr; 105(1):113-21. PubMed ID: 17173958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]